MyFinsight
Home
Compare
Blog
About
Ernexa Therapeutics Inc. (ERNAW)
Ernexa Therapeutics Inc. (ERNAW)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
|
Compare
Cash Flow Overview
Change in Cash
-$4,149K
Free Cash flow
-$4,155K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Stock-based compensation
Other non-current assets
Impairment of goodwill
Others
Negative Cash Flow Breakdown
Accounts payable and accrued exp...
Other liabilities
Prepaid expenses and other curre...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
Gain on lease termination
-
-
0
Paid-in-kind interest expense
-
-
0
Amortization of debt discount and debt issuance costs
-
-
0
Change in fair value of contingent consideration liability
-
-
0
Deferred revenue
-
-
0
Change in fair value of convertible notes
-
-
0
Net loss
-4,015
-5,500
-14,100
Forward sales contract expense
-
0
-5,800
Fair value adjustments to bridge notes derivative liability
-
-
0
Change in fair value of warrant liabilities
-
0
-1
Depreciation and amortization
9
8
65
Stock-based compensation
320
309
1,496
Impairment of right-of-use asset
-
-
33
Loss on disposal of fixed assets
-
-
-13
Accrued interest expense
-
0
22
Amortization of right-of-use asset
35
78
198
Issuance of common stock in connection with settlement
-
-
69
Impairment of goodwill
44
2,000
-
Issuance of common stock to consultant for services
24
96
141
Gain on extinguishment of contingent liability
41
-
800
Other receivables
-12
0
-342
Prepaid expenses and other current assets
59
320
268
Other non-current assets
-85
0
-8
Accounts payable and accrued expenses
-394
759
60
Operating lease liability
-40
-75
-208
Due from related party
0
-750
750
Due to related party
0
-500
750
Other liabilities
-94
93
15
Net cash used in operating activities
-4,152
-2,264
-7,017
Proceeds received from the sale of fixed assets
-
-
0
Purchase of property and equipment
3
2
37
Cash used in investing activities
-3
-2
-37
Fee related to the exercise of prefunded warrants from public offering
-
2
0
Proceeds received from the convertible notes financing
-
-
0
Fees paid related to the convertible notes financing
-
-
0
Proceeds received from bridge notes financing
-
-
0
Proceeds received from notes payable
-
0
2,250
Gross proceeds received from the sale of common stock, prefunded warrants and milestone warrants in public offering
0
10,480
4,929
Fees related to public offering
0
939
-
Gross proceeds received from the exercise of prefunded warrants
0
20
30
Fee related to the exercise of prefunded warrants from public offering
2
-
-
Issuance of common stock under atm
6
-
-
Net cash provided by financing activities
6
9,559
7,209
Net increase in cash
-
7,293
155
Net increase in cash
-4,149
7,293
155
Cash at beginning of period
9,177
1,884
1,729
Cash at end of period
5,028
9,177
1,884
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Issuance of common stock
under atm
$6K
something is missing
$2K
Net cash provided by
financing activities
$6K
Canceled cashflow
$2K
Net increase in cash
-$4,149K
Canceled cashflow
$6K
Stock-based compensation
$320K
Other non-current
assets
-$85K
Impairment of goodwill
$44K
Amortization of right-of-use
asset
$35K
Issuance of common stock
to consultant for...
$24K
Other receivables
-$12K
Depreciation and
amortization
$9K
Fee related to the
exercise of prefunded...
$2K
Net cash used in
operating activities
-$4,152K
Canceled cashflow
$529K
Cash used in
investing activities
-$3K
Net loss
-$4,015K
Accounts payable and
accrued expenses
-$394K
Other liabilities
-$94K
Prepaid expenses and
other current assets
$59K
Gain on
extinguishment of contingent...
$41K
Operating lease liability
-$40K
Purchase of property and
equipment
$3K
Buy us a coffee